165 related articles for article (PubMed ID: 37877506)
21. Trimetazidine can prevent the occurrence of contrast-induced nephropathy after percutaneous coronary intervention in elderly patients with renal insufficiency.
Fu H; Zhang J; Zhang H; Zhang P; Fu X; Zeng Z; Zhang X; Li W; Yang S; Liu X; Fu N
Perfusion; 2021 Sep; 36(6):603-609. PubMed ID: 32909511
[TBL] [Abstract][Full Text] [Related]
22. Effect of Vigileo/FloTrac System-Guided Aggressive Hydration in Acute Myocardial Infarction Patients to Prevent Contrast-Induced Nephropathy After Urgent Percutaneous Coronary Intervention.
Ling W; Jiang Z; Liu K; Zhang H; Qian Y; Tian J; Zhang Z; Chen Y; Qian G
Am J Cardiol; 2023 May; 195():77-82. PubMed ID: 37018968
[TBL] [Abstract][Full Text] [Related]
23. Safety and efficacy of anisodamine on prevention of contrast induced nephropathy in patients with acute coronary syndrome.
Wang YB; Fu XH; Gu XS; Wang XC; Zhao YJ; Hao GZ; Jiang YF; Fan WZ; Wu WL; Li SQ; Xue L
Chin Med J (Engl); 2012 Mar; 125(6):1063-7. PubMed ID: 22613532
[TBL] [Abstract][Full Text] [Related]
24. Effects of remote ischemic preconditioning on contrast induced nephropathy after percutaneous coronary intervention in patients with acute coronary syndrome.
Zhou F; Song W; Wang Z; Yin L; Yang S; Yang F; Song Z; Song Y; Zhang H; Qiao F; Zhang Z
Medicine (Baltimore); 2018 Jan; 97(2):e9579. PubMed ID: 29480853
[TBL] [Abstract][Full Text] [Related]
25. Intravascular ultrasound-guided percutaneous coronary interventions with minimum contrast volume for prevention of the radiocontrast-induced nephropathy: report of two cases.
Ogata N; Matsukage T; Toda E; Tamiya S; Fujii T; Nakazawa G; Masuda N; Morino Y; Ikari Y
Cardiovasc Interv Ther; 2011 Jan; 26(1):83-8. PubMed ID: 24122506
[TBL] [Abstract][Full Text] [Related]
26. CHA2DS2-VASC score as a preprocedural predictor of contrast-induced nephropathy among patients with chronic total occlusion undergoing percutaneous coronary intervention: a single-center experience.
Wang Y; Zhao HW; Zhang XJ; Chen BJ; Yu GN; Hou AJ; Luan B
BMC Cardiovasc Disord; 2019 Mar; 19(1):74. PubMed ID: 30922230
[TBL] [Abstract][Full Text] [Related]
27. Contrast-Induced Nephropathy and Long-Term Clinical Outcomes Following Percutaneous Coronary Intervention in Patients With Advanced Renal Dysfunction (Estimated Glomerular Filtration Rate <30 ml/min/1.73 m
Negishi Y; Tanaka A; Ishii H; Takagi K; Inoue Y; Uemura Y; Umemoto N; Yoshioka N; Morishima I; Asano H; Watarai M; Shibata N; Suzuki S; Murohara T
Am J Cardiol; 2019 Feb; 123(3):361-367. PubMed ID: 30477803
[TBL] [Abstract][Full Text] [Related]
28. Risk of contrast-induced nephropathy in patients undergoing complex percutaneous coronary intervention.
Azzalini L; Poletti E; Lombardo F; Laricchia A; Beneduce A; Moscardelli S; Bellini B; Maccagni D; Cappelletti A; Ancona MB; Carlino M; Chieffo A; Colombo A; Montorfano M
Int J Cardiol; 2019 Sep; 290():59-63. PubMed ID: 31005417
[TBL] [Abstract][Full Text] [Related]
29. Prediction of contrast-induced nephropathy in diabetics undergoing elective percutaneous coronary intervention: role of the ratio of contrast medium volume to estimated glomerular filtration rate.
Wang XC; Fu XH; Wang YB; Jia XW; Wu WL; Gu XS; Zhang J; Su JL; Hao GZ; Jiang YF; Fan WZ; Li SQ
Chin Med J (Engl); 2011 Mar; 124(6):892-6. PubMed ID: 21518598
[TBL] [Abstract][Full Text] [Related]
30. Short-term, high-dose Atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty--contrast-induced nephropathy] trial.
Patti G; Ricottini E; Nusca A; Colonna G; Pasceri V; D'Ambrosio A; Montinaro A; Di Sciascio G
Am J Cardiol; 2011 Jul; 108(1):1-7. PubMed ID: 21529740
[TBL] [Abstract][Full Text] [Related]
31. The predictive value of the renal resistive index for contrast-induced nephropathy in patients with acute coronary syndrome.
Xu ZR; Chen J; Liu YH; Liu Y; Tan N
BMC Cardiovasc Disord; 2019 Feb; 19(1):36. PubMed ID: 30744553
[TBL] [Abstract][Full Text] [Related]
32. Comparison of iodixanol and ioversol for the prevention of contrast-induced nephropathy in diabetic patients after coronary angiography or angioplasty.
Hernández F; Mora L; García-Tejada J; Velázquez M; Gómez-Blázquez I; Bastante T; Albarrán A; Andreu J; Tascón J
Rev Esp Cardiol; 2009 Dec; 62(12):1373-80. PubMed ID: 20038403
[TBL] [Abstract][Full Text] [Related]
33. Febuxostat combined with hydration for the prevention of contrast-induced nephropathy in hyperuricemia patients undergoing percutaneous coronary intervention: A CONSORT-compliant randomized controlled trial.
Ma G; Li M; Teng W; He Z; Zhai X; Xia Z
Medicine (Baltimore); 2022 Jan; 101(4):e28683. PubMed ID: 35089218
[TBL] [Abstract][Full Text] [Related]
34. Impact of the definition utilized on the rate of contrast-induced nephropathy in percutaneous coronary intervention.
Jabara R; Gadesam RR; Pendyala LK; Knopf WD; Chronos N; Chen JP; Viel K; King SB; Manoukian SV
Am J Cardiol; 2009 Jun; 103(12):1657-62. PubMed ID: 19539072
[TBL] [Abstract][Full Text] [Related]
35. Combined use of hydration and alprostadil for preventing contrast-induced nephropathy following percutaneous coronary intervention in elderly patients.
Xu RH; Ma GZ; Cai ZX; Chen P; Zhu ZD; Wang WL
Exp Ther Med; 2013 Oct; 6(4):863-867. PubMed ID: 24137279
[TBL] [Abstract][Full Text] [Related]
36. Impact of Chronic Statin Therapy on Postprocedural Contrast-Induced Nephropathy in Patients Undergoing Non-Emergent Percutaneous Coronary Intervention.
Chanin JM; Yang DC; Haider MA; Swaminathan RV; Kim LK; Charitakis K; Tanoue M; Minutello RM; Gade CL; Singh HS; Bergman G; Wong SC; Feldman DN
J Invasive Cardiol; 2015 Nov; 27(11):490-6. PubMed ID: 25999136
[TBL] [Abstract][Full Text] [Related]
37. Comparison of combination therapy of high-dose oral N-acetylcysteine and intravenous sodium bicarbonate hydration with individual therapies in the reduction of Contrast-induced Nephropathy during Cardiac Catheterisation and Percutaneous Coronary Intervention (CONTRAST): A multi-centre, randomised, controlled trial.
Chong E; Poh KK; Lu Q; Zhang JJ; Tan N; Hou XM; Ong HY; Azan A; Chen SL; Chen JY; Ali RM; Fang WY; Lau TW; Tan HC
Int J Cardiol; 2015 Dec; 201():237-42. PubMed ID: 26301645
[TBL] [Abstract][Full Text] [Related]
38. Contrast-Induced Nephropathy After Percutaneous Coronary Intervention for Chronic Total Occlusion Versus Non-Occlusive Coronary Artery Disease.
Demir OM; Lombardo F; Poletti E; Laricchia A; Beneduce A; Maccagni D; Slavich M; Giannini F; Carlino M; Margonato A; Cappelletti A; Colombo A; Azzalini L
Am J Cardiol; 2018 Dec; 122(11):1837-1842. PubMed ID: 30292337
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness of theophylline in preventing contrast-induced nephropathy after coronary angiographic procedures.
Bilasy ME; Oraby MA; Ismail HM; Maklady FA
J Interv Cardiol; 2012 Aug; 25(4):404-10. PubMed ID: 22612071
[TBL] [Abstract][Full Text] [Related]
40. Clinical Implications of Contrast-Induced Nephropathy in Patients Without Baseline Renal Dysfunction Undergoing Coronary Angiography.
Chen SQ; Liu Y; Smyth B; Li HL; Sun GL; Chen ZJ; Zhou YL
Heart Lung Circ; 2019 Jun; 28(6):866-873. PubMed ID: 29960836
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
